Tredje AP fonden trimmed its position in shares of Edwards Lifesciences Corp (NYSE:EW) by 4.5% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 17,388 shares of the medical research company’s stock after selling 826 shares during the period. Tredje AP fonden’s holdings in Edwards Lifesciences were worth $4,056,000 at the end of the most recent quarter.
A number of other institutional investors and hedge funds have also recently modified their holdings of EW. AdvisorNet Financial Inc increased its stake in Edwards Lifesciences by 39.9% during the third quarter. AdvisorNet Financial Inc now owns 333 shares of the medical research company’s stock valued at $73,000 after acquiring an additional 95 shares during the period. Great West Life Assurance Co. Can increased its holdings in Edwards Lifesciences by 1.1% during the 3rd quarter. Great West Life Assurance Co. Can now owns 280,196 shares of the medical research company’s stock worth $61,609,000 after purchasing an additional 2,924 shares in the last quarter. Sheets Smith Wealth Management increased its holdings in shares of Edwards Lifesciences by 3.6% during the third quarter. Sheets Smith Wealth Management now owns 5,193 shares of the medical research company’s stock worth $1,142,000 after purchasing an additional 181 shares during the period. Brighton Jones LLC bought a new stake in Edwards Lifesciences in the 3rd quarter worth about $245,000. Finally, Cambridge Investment Research Advisors Inc. boosted its stake in Edwards Lifesciences by 0.8% in the third quarter. Cambridge Investment Research Advisors Inc. now owns 17,182 shares of the medical research company’s stock valued at $3,174,000 after acquiring an additional 132 shares during the last quarter. Hedge funds and other institutional investors own 76.83% of the company’s stock.
NYSE EW traded down $2.30 during trading hours on Tuesday, reaching $223.99. 99,834 shares of the company’s stock traded hands, compared to its average volume of 1,404,432. Edwards Lifesciences Corp has a 52-week low of $165.69 and a 52-week high of $247.64. The firm has a market cap of $48.36 billion, a PE ratio of 45.42, a PEG ratio of 2.49 and a beta of 0.78. The firm has a 50-day simple moving average of $231.95 and a 200 day simple moving average of $229.50. The company has a debt-to-equity ratio of 0.16, a current ratio of 3.31 and a quick ratio of 2.60.
Edwards Lifesciences (NYSE:EW) last issued its quarterly earnings results on Thursday, January 30th. The medical research company reported $1.46 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.49 by ($0.03). The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Edwards Lifesciences had a net margin of 24.08% and a return on equity of 31.73%. The company’s revenue was up 20.1% on a year-over-year basis. During the same period last year, the business earned $1.17 earnings per share. Sell-side analysts forecast that Edwards Lifesciences Corp will post 6.26 EPS for the current fiscal year.
In other Edwards Lifesciences news, VP Catherine M. Szyman sold 2,500 shares of the business’s stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $228.57, for a total transaction of $571,425.00. Following the transaction, the vice president now owns 19,389 shares in the company, valued at $4,431,743.73. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Scott B. Ullem sold 7,500 shares of the business’s stock in a transaction on Tuesday, December 10th. The shares were sold at an average price of $233.88, for a total transaction of $1,754,100.00. Following the transaction, the chief financial officer now owns 17,438 shares in the company, valued at approximately $4,078,399.44. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 126,091 shares of company stock worth $29,145,777. 1.63% of the stock is owned by insiders.
A number of analysts recently commented on the stock. Canaccord Genuity restated a “buy” rating on shares of Edwards Lifesciences in a research note on Tuesday. Oppenheimer upgraded shares of Edwards Lifesciences from a “market perform” rating to a “buy” rating and set a $280.00 target price on the stock in a research note on Thursday, January 9th. Stifel Nicolaus increased their target price on shares of Edwards Lifesciences from $275.00 to $280.00 and gave the stock a “buy” rating in a research note on Friday, January 31st. Morgan Stanley increased their target price on shares of Edwards Lifesciences from $248.00 to $270.00 and gave the stock an “overweight” rating in a research note on Friday, December 6th. Finally, Credit Suisse Group increased their target price on shares of Edwards Lifesciences from $275.00 to $278.00 and gave the stock an “outperform” rating in a research note on Friday, January 31st. Three research analysts have rated the stock with a sell rating, six have issued a hold rating and fifteen have assigned a buy rating to the company. The company currently has a consensus rating of “Buy” and an average target price of $249.50.
Edwards Lifesciences Company Profile
Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States and internationally. It offers transcatheter heart valve therapy products comprising transcatheter aortic valve replacement, and transcatheter mitral and tricuspid therapies for the nonsurgical replacement of heart valves.
Recommended Story: Profit Margin
Want to see what other hedge funds are holding EW? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Edwards Lifesciences Corp (NYSE:EW).
Receive News & Ratings for Edwards Lifesciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences and related companies with MarketBeat.com's FREE daily email newsletter.